FDA proposes easing the approval path for cancer companion-diagnostic IHC tests
A proposed order would move immunohistochemistry tests tied to approved cancer drugs from class III to class II, swapping premarket approval for 510(k) clearance plus special controls. Comments close 11 January 2027.
The Food and Drug Administration has proposed to lower the regulatory tier that applies to a large family of cancer diagnostic tests: immunohistochemistry (IHC) test systems that are indicated for use with an approved oncology drug. The proposed order, published in the Federal Register on 12 November 2026 under docket FDA-2026-N-12508, would reclassify these devices from class III, the most stringent tier, into class II [s1]. Comments are due by 11 January 2027 [s1].
The practical consequence is a change in how such a test reaches the market. Class III devices require a premarket approval (PMA) application, the agency's most demanding review. Class II devices instead rely on "special controls" together with a premarket notification — the 510(k) pathway, in which a manufacturer shows its device is substantially equivalent to a legally marketed one [s1]. FDA is proposing to make that shift while writing a set of special controls it says are necessary to keep the tests reliable [s1].
What these tests do
IHC is a staining technique that detects proteins in a tissue specimen. The tests covered by the proposal are prescription in vitro diagnostic devices that use IHC to detect protein expression "qualitatively or quantitatively" and are indicated for use with a corresponding approved oncology therapeutic product [s1]. In cancer care they are the tests that decide whether a given drug is appropriate for a given tumour.
The proposal explicitly covers two uses. The first is companion diagnostics (CDx) — tests that provide information "essential for the safe and effective use" of an approved drug, with that use written into the instructions of both the test and the drug [s1]. The second is tests that report on known benefits or risks of a drug and are referenced in its labelling but are not essential to using it safely [s1]. FDA groups both under a new classification regulation it would create at 21 CFR 864.1895, named "Immunohistochemistry Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product" [s1].
The order reaches a specific, enumerated set of devices, identified by 12 product codes — MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF [s1]. Tests already approved under those codes would be reclassified into class II if the order is finalised, and future tests of the same type would fall under the new regulation as well [s1].
Why FDA says it can drop a tier
The agency is acting under section 513(f)(3) of the Federal Food, Drug, and Cosmetic Act, which lets it reclassify a device on its own initiative when it finds that general and special controls can provide a reasonable assurance of safety and effectiveness [s1]. FDA says it reviewed data from 14 PMAs, published literature on IHC technology, and postmarket information, and concluded that the tests across the 12 product codes share a similar risk profile and similar design features — enough that a single class II regulation with common controls would suffice [s1].
That reasoning rests on the risks being well understood rather than absent. The agency identifies the central hazard plainly: false negative or false positive results [s1]. A wrong result from a test that is essential to a treatment decision could, FDA writes, lead to appropriate therapy being withheld, to a delay in switching to an available alternative, or to a patient receiving inappropriate treatment [s1]. The special controls — analytical and clinical performance testing, labelling requirements and the rest spelled out in the proposed regulation — are the agency's proposed answer to those specific failure modes [s1].
What is settled and what is not
Nothing here is in effect. This is a proposed order inviting comment, and FDA proposes that any final order would take effect 30 days after it is published in the Federal Register [s1]. The agency can alter or drop provisions after reading comments.
The proposal also tidies up a filing error. FDA notes that several of the product codes (NKF, NQF, QUL, QNH, QZJ, SBL, and SER) were mistakenly associated in its databases with an existing regulation for IHC reagents and kits at 21 CFR 864.1860; it says that association was an administrative error and proposes to amend 864.1860's identification language to point these oncology tests to the new 864.1895 instead [s1].
For patients and clinicians, the immediate effect is none — an approved companion test stays approved, and the drugs it is paired with are unaffected. The longer-term question the proposal raises is whether moving this category to 510(k) review speeds the arrival of new companion diagnostics without weakening the validation behind a result that can determine whether someone gets a cancer drug. That trade-off is exactly what the comment period is for, and FDA has not yet finalised anything [s1].
This article describes a proposed federal regulation and is not medical advice.
Sources
- Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product (Proposed amendment; proposed order; request for comments) — U.S. Food and Drug Administration / Federal Register , November 12, 2026
FDA sets a class II path for AI systems that help read Pap-test slides
A final order published 5 November creates a device category for digital cervical cytology imaging systems with AI, letting future versions clear through the 510(k) route instead of the strictest class III review.
FDA firms up Keytruda's tumour-mutation approval and raises the cutoff
On 16 October the FDA converted pembrolizumab's accelerated approval for mutation-heavy solid tumours to full approval, but narrowed it: the qualifying threshold moved from 10 to 13 mutations per megabase.
FDA creates a class II category for at-home STI test kits read in the lab
A final order published 9 October classifies systems that let people collect their own specimens for non-viral STI testing as class II, moving them out of the automatic class III that demands premarket approval.
FDA creates a device class for sinus-vibration stimulators that relieve congestion
A final order codifies 21 CFR 874.6010 for external mechanical stimulators that vibrate the sinus and nasal areas, placing the type in class II after a 2023 De Novo grant for Sound Health Systems' Sonu device.